ArticleJournal of thoracic disease2024

Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer.

Naohiro Yanagimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.